EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Oras A Alabas iD, Kayleigh J Mason iD, Zenas Z N Yiu iD, Catherine H Smith, Richard B Warren iD, Christopher E M Griffiths, BADBIR study group

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf017 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Oras A Alabas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Association of Dermatologists Biologic Register Ltd, British Association of Dermatologists, Almirall.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The current management of psoriasis does not differentiate between younger and older patients in selecting the safest and/or most effective biologic.

Objectives

To explore the effect of age at treatment initiation in response to biologics in patients with moderate-to-severe psoriasis in the UK and Eire.

Methods

Data from patients registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from 2007 to 2024 on a first course of tumour necrosis factor (TNF), interleukin (IL)-12/IL-23, IL-17 and IL-23 inhibitors with at least 6 months’ follow-up were included. Patients aged ≥ 16 years at registration were organized into the following cohorts: 16–24 years, 25–34 years, 35–44 years, 45–54 years, 55–64 years, 65–74 years and ≥ 75 years. The 45–54 years age group was used as the reference cohort. Biologic survival was defined as the time between treatment initiation to its discontinuation associated with ineffectiveness or the occurrence of adverse events (AEs). Adjusted hazard ratios (aHR) with 95% confidence intervals (CIs) was estimated using a flexible parametric model to compare discontinuing treatment between the age groups. Each model included exposure (biologic class), effect modifier (age groups), interaction terms, baseline demographics and clinical and disease severity covariates.

Results

In total, 14 294 patients were included and organized into the following age groups: 16–24 years, n = 847 (5.9%); 25–34 years, n = 2502 (17.5%); 35–44 years, n = 3575 (25.0%); 45–54 years, n = 3863 (27.0%); 55–64 years, n = 2338 (16.4%); 65–74 years, n = 954 (6.8%); and ≥ 75 years, n = 215 (1.5%). The interaction effects model showed that individuals aged 16–24 years were more likely to discontinue TNF inhibitors (TNFi) due to ineffectiveness than those in the reference cohort (aHR 1.30, 95% CI 1.10–1.55). For survival associated with AEs, individuals aged 55–64 years were at higher risk of discontinuing TNFi and IL-12/IL-23 inhibitors [IL-12i/IL-23i; aHR 1.33 (95% CI 1.13–1.56) and aHR 1.34 (95% CI 1.03–1.75), respectively]; those aged 65–74 years were more likely to discontinue TNFi, IL-12i/IL-23i and IL-17 inhibitors [aHR 1.89 (95% CI 1.54–2.31), aHR 2.00 (95% CI 1.47–2.73) and aHR 1.69 (95% CI 1.08–2.64), respectively], whereas individuals aged ≥ 75 years were at higher risk of discontinuing the four biologic classes.

Conclusions

Patients aged 16–24 years with psoriasis are more likely to stop TNFi due to ineffectiveness, whereas those aged ≥ 55 years are more likely to stop biologics due to AEs. These real-world findings provide important information for clinicians treating people with moderate-to-severe psoriasis across all age groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsHumansMiddle AgedMaleFemaleAdultRegistriesAgedAge FactorsUnited KingdomSeverity of Illness IndexYoung AdultAdolescentTreatment OutcomeTumor Necrosis Factor-alphaCohort StudiesImmunologic Factors

Substanzen

Biological ProductsTumor Necrosis Factor-alphaImmunologic Factors

Autor:innen und Institutionen

  • Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester, Manchester, UK.
  • Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
  • St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
  • Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
  • NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Department of Dermatology, King's College Hospital, King's College London, London, UK.

ORCID-Profile: Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Richard B Warren

Förderung

  • British Association of Dermatologists Biologic Register Ltd
  • British Association of Dermatologists
  • Almirall
  • Amgen
  • Eli Lilly
  • Janssen Cilag
  • LEO Pharma
  • National Institute for Health and Care Research

Zitieren

APA

Alabas, O. A., Mason, K. J., Yiu, Z. Z. N., Smith, C. H., Warren, R. B., Griffiths, C. E. M., & BADBIR study group (2025). Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf017

Vancouver

Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Griffiths CEM, et al. Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf017

BibTeX
@article{Alabas2025,
  author = {Alabas, Oras A and Mason, Kayleigh J and Yiu, Zenas Z N and Smith, Catherine H and Warren, Richard B and Griffiths, Christopher E M and BADBIR study group, BADBIR study group},
  title = {Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf017}
}
Kostenlos starten →